News
-
Novartis has announced that its 744-patient randomized, double-blind, 26-week LANTERN study has demonstrated that the once-daily Ultibro Breezhaler indacaterol/glycopyrronium bromide DPI reduced exacerbations in moderate-to-severe COPD patients by 31% compared to twice-daily Advair Diskus (Seretide… Read more . . .
-
Mast Therapeutics has announced that data from an aborted Phase 2 study of AIR001 sodium nitrite inhalation solution for the treatment of pulmonary arterial hypertension (PAH) demonstrated improvement in median pulmonary vascular resistance (PVR) for… Read more . . .
-
Cipla has announced that it has entered into a distribution agreement with S&D Pharma in the Czech Republic and Slovakia in which S&D will distribute Cipla products. The deal includes distribution “in the near future,… Read more . . .
-
Pfizer UK has announced that it has signed an exclusive agreement with Novartis to market the Ultibro Breezhaler indacaterol/glycopyrronium DPI and the Seebri Breezhaler glycopyrronium DPI in the UK for the treatment of COPD. Seebri… Read more . . .
-
Inhaler monitoring company Propeller Health (formerly Asthmapolis) has announced that it raised $14.5 million in a Series B financing round led by Safeguard Scientifics. Safeguard Managing Director Gary J. Kurtzman will join Propeller Health’s board… Read more . . .
-
The FDA has granted fast track designation to Aradigm’s Pulmaquin dual release inhaled ciprofloxacin for treatment of chronic Pseudomonas aeruginosa lung infections in non-cystic fibrosis bronchiectasis patients, the company said. Aradigm initiated a second Phase… Read more . . .
-
Kamada has announced that still plans to hold discussions with the EMA and FDA regarding regulatory submissions for its inhaled Alpha-1 antitrypsin (AAT) even after the drug failed to meet either its primary or secondary… Read more . . .
-
Powder characterization specialists Freeman Technology have announced the opening of an office in Shanghai and the appointment of Joey Xie as Product Manager and Chief Representative in China. The company added that it has also… Read more . . .
-
Teva has announced that the UK High Court has invalidated AstraZeneca’s patent titled “Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma” (EP 1,085,877), which… Read more . . .
-
Cipla has announced the launch of its Serroflo salmeterol/fluticasone MDI, a generic version of Advair, in Germany and Sweden. The inhaler will be available in 25/125 mcg and 25/250 mcg versions, both of which will… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland